Evidence map›Paper›PMID 26134065›Full record

ArticleJournal of endocrinological investigation2016

Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model.

A Aversa, S Fittipaldi, V M Bimonte, F Wannenes, V Papa, D Francomano, E A Greco, A Lenzi, S Migliaccio

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02554045 (Effects of Daily Tadalafil on Body Composition in Men With Sexual Distress), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02554045 phase4completednot on this map

Effects of Daily Tadalafil on Body Composition in Men With Sexual Distress

TypeinterventionalSponsorUniversity of Roma La SapienzaRan2015 to 2015Enrolled20ConditionsObesity, Sexual DysfunctionArmsTadalafil, Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Plants (Basel, Switzerland) · 2022
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

A AversaSection of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy. antonio.aversa@uniroma1.it.
S FittipaldiLisa Laboratory, Policlinico of Catania, University of Catania, Catania, Italy.
V M BimonteLisa Laboratory, Policlinico of Catania, University of Catania, Catania, Italy.
F WannenesLisa Laboratory, Policlinico of Catania, University of Catania, Catania, Italy.
V PapaLisa Laboratory, Policlinico of Catania, University of Catania, Catania, Italy.
D FrancomanoSection of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
E A GrecoSection of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
A LenziSection of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
S MigliaccioSection of Health Sciences, Department of Movement, Human and Health Sciences, "Foro Italico" University of Rome, Largo Lauro De Bosis 15, 00195, Rome, Italy. silvia.migliaccio@uniroma4.it.
University of Catania · ITSapienza University of Rome · ITForo Italico University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePhosphodiesterase type-5 inhibitor (PDE5i) tadalafil administration in men with erectile dysfunction is associated with increased testosterone/estradiol ratio, leading to hypothesize a potential increased effect of androgen action on target tissues. We aimed to characterize, in a cellular model system in vitro, the potential modulation of aromatase and sex steroid hormone receptors upon exposure to tadalafil (TAD).

methodsHuman osteoblast-like cells SAOS-2 were chosen as an in vitro model system since osteoblasts are target of steroid hormones. Cells were tested for viability upon TAD exposure, which increased cell proliferation. Then, cells were treated with/without TAD for several times to evaluate potential modulation in PDE5, aromatase (ARO), androgen (AR) and estrogen (ER) receptor expression.

resultsOsteoblasts express significant levels of both PDE5 mRNA and protein. Exposure of cells to increasing concentrations of TAD (10(-8)-10(-7) M) decreased PDE5 mRNA and protein expression. Also, TAD inhibited ARO mRNA and protein expression leading to an increase in testosterone levels in the supernatants. Interestingly, TAD increased total AR mRNA and protein expression and decreased ERα, with an increased ratio of AR/ER, suggesting preferential androgenic vs estrogenic pathway activation.

conclusionsOur results demonstrate for the first time that TAD decreases ARO expression and increases AR protein expression in human SAOS-2, strongly suggesting a new control of steroid hormones pathway by PDE5i. These findings might represent the first evidence of translational actions of PDE5i on AR, which leads to hypothesize a growing relevance of this molecule in men with prostate cancer long-term treated with TAD for sexual rehabilitation.

Indexed as

AromataseCarcinogenesisCell Line, TumorCell ProliferationCell SurvivalCyclic Nucleotide Phosphodiesterases, Type 5Down-RegulationEnzyme RepressionEstrogen Receptor alphaHumansOsmolar ConcentrationOsteoblastsPhosphodiesterase 5 InhibitorsReceptors, AndrogenRNA, MessengerTadalafilAromataseAR protein, humanCyclic Nucleotide Phosphodiesterases, Type 5CYP19A1 protein, humanESR1 protein, humanEstrogen Receptor alphaPDE5A protein, humanPhosphodiesterase 5 InhibitorsReceptors, AndrogenRNA, MessengerTadalafilTestosteroneAndrogen receptorAromataseEstrogen receptorOsteoblastsTadalafil

Identifiers

PMID26134065
OpenAlexW830129568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.